SEIA
REGN icon

Signature Estate & Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Signature Estate & Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-374
Closed -$237K – 592
2025
Q1 		$237K Buy
374
+47
+14% +$32.3K 0.01% 485
2024
Q4 		$233K Buy
327
+29
+10% +$24.3K 0.01% 473
2024
Q3 		$313K Buy
+298
New +$332K 0.01% 394

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Signature Estate & Investment Advisors's REGN Position: Q2 2025 in Review

Signature Estate & Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 374 shares — an estimated $237K sold.

Signature Estate & Investment Advisors first reported a position in REGN in Q3 2024 and held it in 3 quarters. The position peaked at $313K in Q3 2024. 1,203 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Signature Estate & Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Signature Estate & Investment Advisors sold 374 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $237K.
  • Signature Estate & Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Signature Estate & Investment Advisors's Regeneron Pharmaceuticals position peaked at $313K in Q3 2024.
  • 1,203 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Signature Estate & Investment Advisors's 13F filing for Q2 2025, filed 29 Jul 2025.